• Explore /
  • Poster
  • / Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.

Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.

Abstract Video & Slides Poster

Authors

null

Richard S. Finn

David Geffen School of Medicine at UCLA, Los Angeles, CA

Richard S. Finn , Masatoshi Kudo , Heinz-Josef Klümpen , Ho Yeong Lim , Philippe Merle , Masafumi Ikeda , Gianluca Masi , Catherine T. Frenette , Yoon Jun Kim , René Gerolami , Masayuki Kurosaki , Kazushi Numata , Julia Pisarenko , Kirhan Ozgurdal , Shukui Qin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03289273

DOI

10.1200/JCO.2022.40.4_suppl.433

Abstract #

433

Poster Bd #

C1

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

First Author: Shi-Ming Lin

First Author: Chia Jui Yen

First Author: Jamie Grossman